CA3027286A1 - Method of treating inflammatory bowel disease - Google Patents

Method of treating inflammatory bowel disease Download PDF

Info

Publication number
CA3027286A1
CA3027286A1 CA3027286A CA3027286A CA3027286A1 CA 3027286 A1 CA3027286 A1 CA 3027286A1 CA 3027286 A CA3027286 A CA 3027286A CA 3027286 A CA3027286 A CA 3027286A CA 3027286 A1 CA3027286 A1 CA 3027286A1
Authority
CA
Canada
Prior art keywords
vedolizumab
patient
dose
antibody
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3027286A
Other languages
English (en)
French (fr)
Inventor
Maria Rosario
Morris BAROCAS
Marc R. Gastonguay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA3027286A1 publication Critical patent/CA3027286A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3027286A 2016-06-12 2017-06-12 Method of treating inflammatory bowel disease Pending CA3027286A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349026P 2016-06-12 2016-06-12
US62/349,026 2016-06-12
PCT/US2017/037072 WO2017218434A1 (en) 2016-06-12 2017-06-12 Method of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CA3027286A1 true CA3027286A1 (en) 2017-12-21

Family

ID=59270123

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027286A Pending CA3027286A1 (en) 2016-06-12 2017-06-12 Method of treating inflammatory bowel disease

Country Status (7)

Country Link
US (1) US11389533B2 (cg-RX-API-DMAC7.html)
EP (1) EP3468597A1 (cg-RX-API-DMAC7.html)
JP (1) JP7202893B2 (cg-RX-API-DMAC7.html)
CN (1) CN109414502A (cg-RX-API-DMAC7.html)
CA (1) CA3027286A1 (cg-RX-API-DMAC7.html)
MA (1) MA45245A (cg-RX-API-DMAC7.html)
WO (1) WO2017218434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2022266302A1 (en) * 2021-06-17 2022-12-22 Prometheus Laboratories Inc. Systems and methods for improved targeted therapy
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2002078779A1 (fr) 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
PT1784426E (pt) 2004-09-03 2012-03-06 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
MX338969B (es) 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
ES2646717T3 (es) * 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
TN2017000520A1 (en) 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
CN109071660A (zh) 2016-03-14 2018-12-21 千禧制药公司 预防移植物抗宿主疾病的方法
JP2019512493A (ja) 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire

Also Published As

Publication number Publication date
US20190255172A1 (en) 2019-08-22
EP3468597A1 (en) 2019-04-17
JP2019519544A (ja) 2019-07-11
MA45245A (fr) 2019-04-17
US11389533B2 (en) 2022-07-19
WO2017218434A1 (en) 2017-12-21
CN109414502A (zh) 2019-03-01
JP7202893B2 (ja) 2023-01-12

Similar Documents

Publication Publication Date Title
JP7530314B2 (ja) 抗α４β７インテグリン抗体による治療の結果の予測
JP7275223B2 (ja) ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
US12246064B2 (en) Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
KR20150074179A (ko) 리실 옥시다제-유사 2 (loxl2)와 관련된 치료 및 진단 방법
JP6942053B2 (ja) 原発性硬化性胆管炎を治療する方法
US11389533B2 (en) Method of treating inflammatory bowel disease
AU2025202525A1 (en) Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
US20230382978A1 (en) Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
US11845790B2 (en) SH3YL1 antibodies, compositions comprising the same, and vectors and uses thereof
CA3190526A1 (en) Methods for reducing maternal autoantibodies
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
KR20230145929A (ko) CD1a 항체 및 그의 용도
EA045594B1 (ru) Антитела к b7-h4 и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220610

EEER Examination request

Effective date: 20220610

EEER Examination request

Effective date: 20220610

EEER Examination request

Effective date: 20220610

EEER Examination request

Effective date: 20220610